The Patent Finder

Mablife

Also on record
Records under this name other than the patents Mablife holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.

Showing 1 to 4 of 4 · Back to Mablife

PatentTitleStatus Expires Confidence
US 7,153,506Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
Term ended
Term ended Jan 7, 2022 · From the USPTO record
Term endedTerm ended Jan 7, 2022From the USPTO record
US 8,728,477Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof
Formerly held
Lapsed on the fee record
Ended May 20, 2018 · From the USPTO record
Lapsed on the fee recordEnded May 20, 2018From the USPTO record
US 8,409,573ANTI-CD71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells
Lapsed on the fee record
Ended Apr 2, 2017 · High confidence
Lapsed on the fee recordEnded Apr 2, 2017High confidence
US 7,736,647ANTI-CD71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells
Lapsed on the fee record
Ended Jun 15, 2014 · High confidence
Lapsed on the fee recordEnded Jun 15, 2014High confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited